HealthDay News — Transcutaneous electrical nerve stimulation (TENS) plus outpatient physical therapy (PT) reduces movement-based pain in patients with fibromyalgia, according to a study published ...

The proposed 2027 budget would give HHS about $111.1 billion, down roughly $15.8 billion from its current funding. The plan comes from President Donald Trump, but Congress will decide what actually ...

HealthDay News — Treatment with upadacitinib is safe and effective for adults and adolescents with nonsegmental vitiligo (NSV), according to a study presented at the annual meeting of the American ...

KT may reduce pain intensity in immediate, short term and improve function/disability in immediate term, but evidence is ...

A unanimous United States Supreme Court decision has now removed a significant procedural hurdle for medical malpractice plaintiffs in 28 states. In this case, the Court was asked to determine whether ...

More than tripled risk of five-year mortality seen with use of complementary and alternative medicine alone compared with traditional therapies.

The FDA is expected to decide on treatments for ADHD, Alzheimer disease, breast cancer, diabetes, and myasthenia gravis.

The TEPEZZA OBI trial evaluated the safety and efficacy of SC teprotumumab in patients with active TED and proptosis of 3mm or greater from baseline.

The new advice comes as federal dietary guidance has taken a much different stance. Health officials, alongside US Health Secretary Robert F. Kennedy Jr., have suggested people can include more red ...

HealthDay News — For patients with postacute sequelae of SARS-CoV-2, fluvoxamine seems effective for reducing fatigue and improving quality of life (QoL), according to a study published online March ...

The table below is a review of notable updates that occurred in March 2026 for investigational products in development (not an inclusive list). Click on the status to view our full coverage. GZR4 (Gan ...

More participants felt "much more" in control of their diabetes, eating, and weight after switching to tirzepatide vs escalating dulaglutide. HealthDay News — For adults with type 2 diabetes (T2D) who ...